Media headlines about IGI Laboratories (NYSE:IG) have trended positive recently, Accern Sentiment reports. Accern identifies negative and positive news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. IGI Laboratories earned a media sentiment score of 0.30 on Accern’s scale. Accern also assigned media stories about the company an impact score of 46.2196302951127 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Shares of IGI Laboratories (NYSE:IG) remained flat at $7.68 during trading on Wednesday. The company has a 50-day moving average price of $7.71 and a 200-day moving average price of $7.24. IGI Laboratories has a 12 month low of $4.75 and a 12 month high of $12.05.
TRADEMARK VIOLATION WARNING: “IGI Laboratories (NYSE:IG) Earns Daily Coverage Optimism Score of 0.30” was originally published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this news story on another site, it was stolen and republished in violation of US and international copyright & trademark laws. The correct version of this news story can be viewed at https://ledgergazette.com/2017/10/19/igi-laboratories-ig-receiving-favorable-media-coverage-study-finds.html.
About IGI Laboratories
IGI Laboratories, Inc is a specialty generic pharmaceutical company. Under its IGI label, the Company sells generic topical pharmaceutical products that are bioequivalent to their brand name counterparts. The Company provides development, formulation and manufacturing services to the pharmaceutical, over-the-counter (OTC) and cosmetic industries.
Receive News & Ratings for IGI Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IGI Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.